Rescue of p53 function by MDM2 antagonist, Nutlin-3, enhances the apoptotic synergism between MEK1 inhibitor and arsenic trioxide

被引：0
|
作者：
Lunghi, P.
Mazzera, L.
Rizzoli, V.
Bonati, A.
机构：
[1] Univ Parma, Dept Clin Sci, I-43100 Parma, Italy
[2] Univ Parma, Hematol Unit, I-43100 Parma, Italy
[3] Univ Parma, Dept Internal Med, I-43100 Parma, Italy
来源：
EXPERIMENTAL HEMATOLOGY | 2007年 / 35卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：86 / 86
页数：1
相关论文
共 50 条
  • [1] MDM2 antagonist Nutlin-3 activates p53 and enhances the apoptotic synergism between MEK inhibitor and arsenic trioxide (ATO) in AML cells
    Lunghi, P.
    Mazzera, L.
    Rizzoli, V
    Bonati, A.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 51 - 52
  • [2] Mdm2 inhibitor nutlin-3 enhances the cytotoxic synergism induced by the combination of MEK1 inhibitor and arsenic trioxide (ATO) in AML cells.
    Lunghi, Paolo
    Mazzera, Laura
    Rizzoli, Vittorio
    Bonati, Antonio
    [J]. BLOOD, 2006, 108 (11) : 398A - 398A
  • [3] The MDM2 Inhibitor Nutlin-3 But Not the p53 Activator RITA Induces Loss-of-function p53 Mutations
    Michaelis, M.
    Rothweiler, F.
    Barth, S.
    Cinatl, J.
    van Rikxoort, M.
    von Deimling, A.
    Roedel, F.
    Speidel, D.
    Cinatl, J., Jr.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : 43 - 43
  • [4] MDM2 INHIBITION SYNERGISTICALLY ENHANCES CYTOTOXICITY OF MEK1 INHIBITOR AND ARSENIC TRIOXIDE (ATO) IN AML BLASTS THAT RETAIN A FUNCTIONAL P53 PATHWAY
    Mazzera, L.
    Lunghi, P.
    Mangoni, M.
    Caramatti, C.
    Rizzoli, V
    Bonati, A.
    [J]. HAEMATOLOGICA, 2008, 93 : S47 - S47
  • [5] Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53
    He, Tianli
    Guo, Jiayou
    Song, Hongmei
    Zhu, Hongcheng
    Di, Xiaoke
    Min, Hua
    Wang, Yuandong
    Chen, Guangzong
    Dai, Wangshu
    Ma, Jianhua
    Sun, Xinchen
    Ma, Jianxin
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2018, 24 (01) : 75 - 81
  • [6] The MDM2 antagonist nutlin-3 is lethal to mantle cell lymphoma with wild type p53
    Tabe, Yoko
    Szbasigari, Denise
    Rudelius, Martina
    Pittaluga, Stefania
    Raffel, Mark
    [J]. BLOOD, 2007, 110 (11) : 415A - 415A
  • [7] p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3
    Chappell, William H.
    Lehmann, Brian D.
    Terrian, David M.
    Abrams, Stephen L.
    Steelman, Linda S.
    McCubrey, James A.
    [J]. CELL CYCLE, 2012, 11 (24) : 4579 - 4588
  • [8] Mdm2 antagonist Nutlin-3 induces apoptosis in p53 mutant human colon carcinoma cells
    Bhattacharya, Sujoy
    Ray, Ramesh M.
    Johnson, Leonard R.
    [J]. FASEB JOURNAL, 2009, 23
  • [9] p53 mutations induced by the MDM2 inhibitor nutlin-3 in p53 wild-type neuroblastoma cells
    Michaelis, M.
    Wass, M.
    Cinatl, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S72 - S72
  • [10] How Nutlin-3 disrupts the MDM2–p53 interaction: a theoretical investigation
    Shah Md. Abdur Rauf
    Hiromitsu Takaba
    Carlos A. Del Carpio
    Akira Miyamoto
    [J]. Medicinal Chemistry Research, 2014, 23 : 1998 - 2006
12345